Prognostic impact of Deoxyribonucleic acid (DNA) image analysis cytometry and immunohistochemical expression of Ki67 in surgically resected non-small cell lung cancers

Cancer Detection and Prevention

Volumn 30, Issue 6, 2006, Pages 507-514

  Maounis, Nicoletta F ^a   Chorti, Maria ^a   Apostolakis, Efstratios ^b   Ellina, Eleni ^a   Blana, Aikaterini ^a   Aggelidou, Maria ^a   Dritsas, Ioannis ^a   Markidou, Sophia ^c  

^a SISMANOGLIO HOSPITAL   (Greece)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^c HYGEIA HOSPITAL   (Greece)

Author keywords

Aneuploid tumors; DNA image cytometry; DNA ploidy; Image analysis; Immunohistochemistry; Ki67; Non small cell lung carcinoma; Patient survival; Prognosis

Indexed keywords

AVIDIN; BIOTIN; DNA; KI 67 ANTIGEN; PEROXIDASE;

ADENOCARCINOMA; ADULT; AGED; ANALYTIC METHOD; ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DNA DETERMINATION; ENDOREDUPLICATION; FEMALE; HISTOGRAM; HUMAN; IMAGE ANALYSIS; IMAGE CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INDEPENDENT VARIABLE; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MULTIVARIATE ANALYSIS; PLOIDY; POLYPLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DNA, NEOPLASM; FEMALE; HUMANS; IMAGE CYTOMETRY; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PLOIDIES; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 37849185039     PISSN: 0361090X     EISSN: 15251500     Source Type: Journal    
DOI: 10.1016/j.cdp.2006.07.007     Document Type: Article

References (55)

1. U.S. Cancer Statistics: 2002 incidence and mortality, U.S. Cancer Statistics Working Group 2005 and National Vital Statistics Report. 2004; 53(5). Available from URL: http://www.cdc.gov/lungcancer/statistics/index.htm [accessed January 5, 2006].
2. Ponn R., LoCicero J., and Daly B. Surgical treatment of non-small cell lung cancer. In: Shields T., LoCicero J., Ponn R., and Rusch V. (Eds). General thoracic surgery. 6th ed. (2005), Lippincott Williams and Wilkins, Philadelphia 1559-1560
3. Tanaka F., Yanagihara K., Otake Y., Yamada T., Shoji T., Miyahara R., et al. Prognostic factors in patients with resected pathologic (p-) T1-2N1Mo non-small cell lung cancer (NSCLC). Eur J Cardiothorac Surg 19 (2001) 555-561
4. Rena O., Oliaro A., Cavallo A., Filosso P.L., Donati G., Di Marzio P., et al. Stage I non-small cell lung carcinoma: really an early stage?. Eur J Cardiothorac Surg 21 (2002) 514-519
5. Thomas P., Doddoli C., Thirion X., Ghez O., Payan-Defais M.J., Giudicelli R., et al. Stage I non-small cell lung cancer: a pragmatic approach to prognosis after complete resection. Ann Thorac Surg 73 (2002) 1065-1070
6. Cohen C. Image cytometric analysis in pathology. Hum Pathol 27 (1996) 482-493
7. El-Naggar A.K., and Vielh P. Solid tumor DNA content analysis. Methods Mol Biol 263 (2004) 355-370
8. Alderisio M., Cenci M., Valli C., Russo A., Bazan V., Dardanoni G., et al. Nm23-H1 protein, DNA ploidy and S-phase fraction in relation to overall survival and disease free survival in transitional cell carcinoma of the bladder. Anticancer Res 18 (1998) 4225-4230
9. Tribukait B., Gustafson H., and Esposti P.L. The significance of ploidy and proliferation in the clinical and biological evaluation of bladder tumors: a study of 100 untreated cases. Br J Urol 54 (1982) 130-135
10. Bostwick D.G. Practical clinical application of predictive factors in prostate cancer. A review with an emphasis on quantitative methods in tissue specimens. Anal Quant Cytol Histol 20 (1998) 323-342
11. Susini T., Rapi S., Massi D., Savino L., Amunni G., Taddei G.L., et al. Preoperative evaluation of tumor ploidy in endometrial carcinoma: an accurate tool to identify patients at risk for extrauterine disease and recurrence. Cancer 86 (1999) 1005-1012
12. Sudbo J., Lippman S.M., Lee J.J., Mao L., Kildal W., Sudbo A., et al. The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med 350 (2004) 1405-1413
13. Moureau-Zabotto L., Bouchet C., Cesari D., Uzan S., Lefranc J.P., Antoine M., et al. Combined flow cytometric determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancer. Breast Cancer Res Treat 91 (2005) 61-71
14. Ross W., and Hall P.A. Ki67: from antibody to molecule to understanding?. J Clin Pathol: Mol Pathol 48 (1995) 113-117
15. Molino A., Micciolo R., Turazza M., Bonetti F., Piubello Q., Bonetti A., et al. Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis. Int J Cancer 74 (1997) 433-437
16. Bubendorf L., Tapia C., Gasser T.C., Casella R., Grunder B., Moch H., et al. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol 29 (1998) 949-954
17. Bol M.G., Baak J.P., van Diermen B., Buhr-Wildhagen S., Janssen E.A., Kjellevold K.H., et al. Proliferation markers and DNA content analysis in urinary bladder TaTi urothelial cell carcinomas: identification of subgroups with low and high stage progression risks. J Clin Pathol 56 (2003) 447-452
18. Petit B., Chaury M.P., Le Clorennec C., Jaccard A., Gachard N., Moalic-Judge S., et al. Indolent lymphoplasmacytic and marginal zone B-cell lymphomas: absence of both IRF4 and Ki67 expression identifies a better prognostic subgroup. Haematologica 90 (2005) 200-206
19. World Health Organization. Histological typing of lung tumours. International histological classification of tumours. 2nd ed. vol. 1 (1981), World Health Organization, Geneva
20. American Joint Commission on Cancer. AJCC cancer staging manual. 5th ed. (1997), Lippincott-Raven, Philadelphia p. 127-133
21. Scagliotti G.V., Micela M., Gubetta L., Leonardo E., Cappia S., Borasio P., et al. Prognostic significance of Ki67 labelling in resected non-small cell lung cancer. Eur J Cancer 29A (1993) 363-365
22. Huang C., Liu D., Masuya D., Nakashima T., Kameyama K., Ishikawa S., et al. Clinical application of biological markers for treatments of resectable non-small-cell lung cancers. Br J Cancer 92 (2005) 1231-1239
23. Mehdi S.A., Etzell J.E., Newman N.B., Weidner N., Kohman L.J., and Graziano S.L. Prognostic significance of Ki-67 immunostaining and symptoms in resected stage I and II non-small cell lung cancer. Lung Cancer 20 (1998) 99-108
24. Haroske G., Baak J.P., Danielsen H., Giroud F., Gschwendtner A., Oberholzer M., et al. Fourth updated ESACP consensus report on diagnostic DNA image cytometry. Anal Cell Pathol 23 (2001) 89-95
25. Pelletier M.P., Edwardes M.D., Michel R.P., Halwani F., and Morin J.E. Prognostic markers in resectable non-small cell lung cancer: multivariate analysis. Can J Surg 44 (2001) 180-188
26. Gawrychowski J., Lackowska B., and Gabriel A. Prognosis of the surgical treatment of patients with non-small cell lung cancer (NSCLC)-relation to DNA ploidy. Eur J Cardiothorac Surg 23 (2003) 870-877
27. Hofmann H.S., Knolle J., Bahn H., Klapperstück T., Lautenschläger C., and Neef H. Flow cytometric analysis of DNA content and proliferation and immunohistochemical staining of Ki-67 in non-small cell lung cancer. J Cardiovasc Surg (Torino) 42 (2001) 555-560
28. Rice T.W., Bauer T.W., Gephardt G.N., Medendorp S.V., McLain D.A., and Kirby T.J. Prognostic significance of flow cytometry in non-small cell lung cancer. J Thorac Cardiovasc Surg 106 (1993) 210-217
29. Otsuka H., Funai S., Tanaka A., Hara S., and Shiozaki H. Stratification of the biologic aggressiveness of non-small cell lung cancer using DNA flow cytometry and immunohistochemistry for the retinoblastoma protein. Lung Cancer 45 (2004) 307-316
30. Filderman A.E., Silvestri G.A., Gatsonis C., Luthringer D.J., Honig J., and Flynn S.D. Prognostic significance of tumor proliferative fraction and DNA content in stage I non-small cell lung cancer. Am Rev Respir Dis 146 (1992) 707-710
31. Kolodziejski L., Niezabitowski A., and Gasinska A. Clinical and flow cytometric prognostic factors in surgically treated squamous cell lung cancer. Lung Cancer 16 (1997) 173-182
32. Choma D., Daurès J.P., Quantin X., and Pujol J.L. Aneuploidy and prognosis of non-small cell lung cancer: a meta-analysis of published data. Br J Cancer 85 (2001) 14-22
33. Reinmuth N., Brandt B., Kunze W.P., Junker K., Thomas M., Achatzy R., et al. Ploidy, expression of erbB1, erbB2, p53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer. Eur Respir J 16 (2000) 991-996
34. Dalquen P., Moch H., Feichter G., Lehmann M., Soler M., Stulz P., et al. DNA aneuploidy, S-phase fraction, nuclear p53 positivity, and survival in non-small cell lung carcinoma. Virchows Arch 431 (1997) 173-179
35. Lavezzi A.M., Santambrogio L., Bellaviti N., Biondo B., Nosotti M., Radice F., et al. Prognostic significance of different biomarkers in non-small cell lung cancer. Oncol Rep 6 (1999) 819-825
36. Van Bodegom P.C., Baak J.P., Stroet-van Galen C., Schipper N.W., Wisse-Brekelmans E.C., Vanderschueren R.G., et al. The percentage of aneuploid cells is significantly correlated with survival in accurately staged patients with stage 1 resected squamous cell lung cancer and long term follow-up. Cancer 63 (1989) 143-147
37. Pina T.C., Zapata I.T., Lopez J.B., Perez J.L., Paricio P.P., and Hernandez P.M. DNA aneuploidy, S-phase fraction and nuclear p53 positivity in non-small cell lung carcinoma. Clin Biochem 32 (1999) 347-354
38. Puech M., and Giroud F. Standardisation of DNA quantitation by image analysis: quality control of instrumentation. Cytometry 36 (1999) 11-17
39. Pence J.C., Kerns B.J., Dodge R.K., and Iglehart J.D. Prognostic significance of the proliferation index in surgically resected non-small cell lung cancer. Arch Surg 128 (1993) 1382-1390
40. Chen T.L., Luo I., Mikhail N., Raskova J., and Raska Jr. K. Comparison of flow and image cytometry for DNA content analysis of fresh and formalin-fixed, paraffin-embedded tissue in breast carcinoma. Cytometry 22 (1995) 181-189
41. Lee A.K., Dugan J., Hamilton W.M., Cook L., Heatley G., Kamat B., et al. Quantitative DNA analysis in breast carcinomas: a comparison between image analysis and flow cytometry. Mod Pathol 4 (1991) 178-182
42. Verderio P., Corletto V., Boracchi P., Gambacorta M., and Giardini R. Evaluation of the reproducibility of Auer's classification of DNA histogram in breast carcinoma. Anal Cell Pathol 11 (1996) 97-106
43. Pujol J.L., Simony J., Jolimoy G., Jaffuel D., Demoly P., Quantin X., et al. Hypodiploidy, Ki-67 growth fraction and prognosis of surgically resected lung cancers. Br J Cancer 74 (1996) 964-970
44. Simony J., Pujol J.L., Radal M., Ursule E., Michel F.B., and Pujol H. In situ evaluation of growth fraction determined by monoclonal antibody Ki-67 and ploidy in surgically resected non-small cell lung cancers. Cancer Res 50 (1990) 4382-4387
45. Rigau V., Molina T.J., Chaffaud C., Huchon G., Audouin J., Chevret S., et al. Blood vessel invasion in resected non small cell lung carcinomas is predictive of metastatic occurrence. Lung Cancer 38 (2002) 169-176
46. Carbognani P., Tincani G., Crafa P., Sansebastiano G., Pazzini L., Zoni R., et al. Biological markers in non-small cell lung cancer. Retrospective study of 10 year follow-up after surgery. J Cardiovasc Surg (Torino) 43 (2002) 545-548
47. D'Amico T.A., Massey M., Herndon II J.E., Moore M.B., and Harpole Jr. D.H. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 117 (1999) 736-743
48. Minami K., Saito Y., Imamura H., and Okamura A. Prognostic significance of p53, Ki67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung. Lung Cancer 38 (2002) 51-57
49. Shiba M., Kohno H., Kakizawa K., Iizasa T., Otsuji M., Saitoh Y., et al. Ki-67 immunostaining and other prognostic factors including tobacco smoking in patients with resected nonsmall cell lung carcinoma. Cancer 89 (2000) 1457-1465
50. Martin B., Paesmans M., Mascaux C., Berghmans T., Lothaire P., Meert A.P., et al. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 91 (2004) 2018-2025
51. Lindboe C.F., and Torp S.H. Comparison of Ki67 equivalent antibodies. J Clin Pathol 55 (2002) 467-471
52. Lee J.S., Yoon A., Kalapurakal S.K., Ro J.Y., Lee J.J., Tu N., et al. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol 13 (1995) 1893-1903
53. Spyratos F., Ferrero-Pous M., Trassard M., Hacene K., Phillips E., Tubiana-Hulin M., et al. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer 94 (2002) 2151-2159
54. KIPI protein and Ki-67 growth fraction in non-small cell lung cancers. Clin Cancer Res 6 (2000) 4073-4081
55. Macdonald C., Michael A., Colston K., and Mansi J. Heterogeneity of immunostaining for tumor markers in non-small cell lung carcinoma. Eur J Cancer 40 (2004) 461-466